Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bis-difluromethoxyphenyl)-2-{4-(1,1,1,3,3,3- hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 310, Issue 2, 2004, Pages 752-760

  Claveau, D ^b   Chen, S L ^a   O'Keefe, S ^a   Zaller, D M ^a   Styhler, A ^b   Liu, S ^b   Huang, Z ^b   Nicholson, D W ^b   Mancini, Joseph A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (3,4 BISDIFLUOROMETHOXYPHENYL) 2 [4 (1,1,1,3,3,3 HEXAFLUORO 2 HYDROXYPROPAN 2 YL)PHENYL]ETHYL] 3 METHYLPYRIDINE 1 OXIDE; CD28 ANTIGEN; CD3 ANTIGEN; CYCLIC AMP; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; L 826 141; OVALBUMIN; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4C; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; EFFECTOR CELL; ENZYME MECHANISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PHOSPHODIESTERASE INHIBITORS; PYRIDINES; TH1 CELLS; TH2 CELLS;

EID: 3342988190     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.064691     Document Type: Article

References (44)

1. Barnes PJ (2003) Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 97:87-94.
2. Bielokova B, Lincoln A, McFarland H, and Martin R (2000) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164:1117-1124.
3. Broide DH, Paine MM, and Firestein GS (1992) Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Investig 90:1414-1424.
4. Chen SL, Whiteley PJ, Freed DC, Rothbard JB, Peterson LB, and Wicker LS (1994) Responses of NOD congenic mice to a glutamic acid decarboxylase-derived peptide. J Autoimmun 7:635-641.
5. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, et al. (2001) Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358:265-270.
6. Conti M, Richter W, Mehats C, Livera G, Park JY, and Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496.
7. Cooper DM, Mons N, and Karpen JW (1995) Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature (Lond) 374:421-424.
8. Dym O, Xenarios I, Ke H, and Colicelli J (2002) Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 61:20-25.
9. Foissier L, Lonchampt M, Coge F, and Canet E (1996) In vitro down-regulation of antigen induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor. J Pharmacol Exp Ther 278:1484-1490.
10. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, and Torphy TJ (1998) SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor a and interleukin-4 production in vivo. J Pharmacol Exp Ther 287:705-711.
11. Hansen G, Jin S, Umetsu DT, and Conti M (2000) Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97:6751-6756.
12. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, et al. (1997) The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 10:1008-1014.
13. Hatzelmann A and Schudt C (2001) Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297:267-279.
14. Hogan SP, Mould A, Kikutani H, Ramsay AJ, and Foster PS (1997) Aeroallergen-induced eosinophilic inflammation, lung damage and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Investig 99:1329-1339.
15. Horiuchi T and Castro M (2000) The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma. Clin Chest Med 21:381-395.
16. Houslay MD and Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18.
17. Houslay MD and Milligan G (1997) Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 22:217-224.
18. Huang Z, Ducharme Y, Macdonald D, and Robichaud A (2001) The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5:432-438.
19. Iyengar R (1993) Molecular and functional diversity of mammalian Gs-stimulated adenylyl cyclases. FASEB J 7:768-775.
20. Jin SL and Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99:7628-7633.
21. Kavelaars A, Zijlstra J, Bakker JM, Van Rees EP, Visser GH, Zegers BJ, and Heijnen CJ (1995) Increased dexamethasone sensitivity of neonatal leukocytes: different mechanisms of glucocorticoid inhibition of T cell proliferation in adult and neonatal cells. Eur J Immunol 25:1346-1351.
22. Krupinski J, Coussen F, Bakalyar HA, Tang WJ, Feinstein PG, Orth K, Slaughter C, Reed RR, and Gilman AG (1989) Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure. Science (Wash DC) 244:1558-1564.
23. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, and Huang Z (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39:6449-6458.
24. Li L, Yee C, and Beavo JA (1999) CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science (Wash DC) 283:848-851.
25. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, and Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40:10179-10186.
26. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
27. Muise ES, Chute IC, Claveau D, Masson P, Boulet L, Tkalec L, Pon DJ, Girard Y, Frenette R, and Mancini JA (2002) Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem Pharmacol 63:1527-1535.
28. Murphy KM, Heimberger AB, and Loh DY (1990) Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science (Wash DC) 250:1720-1723.
29. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, et al. (2002) Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science (Wash DC) 298:834-836.
30. Prieto J, Van DP, I, Roquet A, Gigliotti D, Dahlen B, Eklund A, and Grunewald J (2001) Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation. Clin Exp Allergy 31:791-800.
31. Profita M, Chiappara G, Mirabella F, Di Giorgi R, Chimenti L, Costanzo G, Riccobono L, Bellia V, Bousquet J, and Vignola AM (2003) Effect of cilomilast (Ariflo) on TNF-alpha, IL-8 and GM-CSF release by airway cells of patients with COPD. Thorax 58:573-579.
32. Renauld JC (2001) New insights into the role of cytokines in asthma. J Clin Pathol 54:577-589.
33. Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, and Chan CC (2001) PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40:262-269.
34. Robison GA, Butcher RW, and Sutherland EW (1968) Cyclic AMP. Annu Rev Biochem 37:149-174.
35. Semmler J, Wachtel H, and Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 15:409-413.
36. Simonds WF (1999) G protein regulation of adenylate cyclase. Trends Pharmacol Sci 20:66-73.
37. Sturton G and Fitzgerald M (2002) Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 121:192S-196S.
38. Sunahara RK, Dessauer CW, and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480.
39. Taussig R and Gilman AG (1995) Mammalian membrane-bound adenylyl cyclases. J Biol Chem 270:1-4.
40. Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T, and Wurst W (2002) The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 42:297-303.
41. Vink A, Warnier G, Brombacher F, and Renauld JC (1999) Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population. J Exp Med 189:1413-1423.
42. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, and Umetsu DT (2001) Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 167:4668-4675.
43. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science (Wash DC) 288:1822-1825.
44. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, and Watson AJ (2003) J Immunol 171:6414-6420.